Research graph
References from A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis. Local targets link to admitted publications; unresolved targets remain external evidence.
Functional tumor-derived exosomes in NSCLC progression and clinical implications
2025 · External reference
Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases
2025 · External reference
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
10.1186/s13045-022-01347-8 · 2022 · External reference
How compensatory mechanisms and adaptive rewiring have shaped our understanding of therapeutic resistance in cancer
10.1158/0008-5472.can-21-3605 · 2021 · External reference
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
10.1038/s41568-022-00454-5 · 2022 · External reference
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
10.1186/s12964-024-01607-9 · 2024 · External reference
Innovative approaches for molecular targeted therapy of breast cancer: interfering with various pathway signaling
2025 · External reference
Entrectinib, a new multi-target inhibitor for cancer therapy
10.1016/j.biopha.2022.112974 · 2022 · External reference
Functional materials for subcellular targeting strategies in cancer therapy: progress and prospects
2023 · External reference
Subcellular organelle targeting as a novel approach to combat tumor metastasis
10.3390/pharmaceutics17020198 · 2025 · External reference
The role of lysosomes in cancer development and progression
10.1186/s13578-020-00489-x · 2020 · External reference
Hypoxia-reprogramed megamitochondrion contacts and engulfs lysosome to mediate mitochondrial self-digestion
10.1038/s41467-023-39811-9 · 2023 · External reference
Concurrent impairment of nucleus and mitochondria for synergistic inhibition of cancer metastasis
10.1016/j.ijpharm.2021.121077 · 2021 · External reference
Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring
10.1016/j.jpha.2023.11.006 · 2024 · External reference
Potential synthetic lethality for breast cancer: a selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib
10.1016/j.phrs.2021.106050 · 2022 · External reference
IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity
2025 · External reference
Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells
10.1371/journal.pone.0114787 · 2014 · External reference
Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent axis
10.1186/s13046-020-01768-8 · 2020 · External reference
PARP inhibitor olaparib overcomes sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
10.1186/s12943-021-01315-9 · 2021 · External reference
Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma
10.1038/s41419-019-1989-z · 2019 · External reference
Esterase-activated theranostic prodrug for dual organelles-targeted imaging and synergetic chemo-photodynamic cancer therapy
10.31635/ccschem.021.202100985 · 2022 · External reference
Targeting CD8+ T cells with natural products for tumor therapy: revealing insights into the mechanisms
10.1016/j.phymed.2024.155608 · 2024 · External reference
Curcumin and analogues against head and neck cancer: from drug delivery to molecular mechanisms
10.1016/j.phymed.2023.154986 · 2023 · External reference
Curcumin and its analogs as potential epigenetic modulators: prevention of diabetes and its complications
10.1159/000520311 · 2022 · External reference
PLGA nanoparticles loaded with curcumin produced luminescence for cell bioimaging
10.1016/j.ijpharm.2023.122944 · 2023 · External reference
PLGA confers upon conventional nonfluorescent molecules luminescent properties to trigger 1O2-induced pyroptosis and immune response in tumors
10.1186/s12951-025-03094-7 · 2025 · External reference
Cellular organelle-targeted smart AIEgens in tumor detection, imaging and therapeutics
2022 · External reference
Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
10.1016/j.addr.2024.115239 · 2024 · External reference
Ligand-installed nanocarriers toward precision therapy
2020 · External reference
Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy
10.1039/d0nh00469c · 2021 · External reference
Synthesis, evaluation, and biocompatibility study of magnetite nano particles in normal cells and cancer cells for health care application
10.1016/j.nanoso.2024.101313 · 2024 · External reference
Development of high‐drug‐loading nanoparticles
10.1002/cplu.202000496 · 2020 · External reference
Tailoring carrier-free nanoparticles based on natural small molecule assembly for synergistic anti-tumor efficacy
2025 · External reference
Janus microneedles enabling orderly vitiligo treatment through spatiotemporal sequential promoting melanogenesis to transfer via PAR2 activation
2026 · External reference
Albumin nanoassembly bi-directionally manipulated ferroptosis in tumor and CD8+ T cells for triple-negative breast cancer therapy
2025 · External reference
Medicinal plant using ground state stabilization of natural antioxidant curcumin by keto-enol tautomerisation
10.1007/s13659-018-0170-1 · 2018 · External reference
Alkyl chain length-regulated in situ intelligent nano-assemblies with AIE-active photosensitizers for photodynamic cancer therapy
2024 · External reference
Every step of the way: integrins in cancer progression and metastasis
10.1038/s41568-018-0038-z · 2018 · External reference
Diallyl disulfide attenuates ionizing radiation-induced migration and invasion by suppressing Nrf2 signaling in non-small-cell lung cancer
10.1177/15593258211033114 · 2021 · External reference
Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis
10.1038/nature25486 · 2018 · External reference
Response to precision medicine: current subcellular targeting strategies for cancer therapy
2023 · External reference
BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network
10.1038/s41586-022-05551-x · 2023 · External reference
Nuclear ANLN regulates transcription initiation related Pol II clustering and target gene expression
10.1038/s41467-025-56645-9 · 2025 · External reference
Nuclear receptors: recent drug discovery for cancer therapies
2019 · External reference
Sorafenib promotes treg cell differentiation to compromise its efficacy via VEGFR/AKT/Foxo1 signaling in hepatocellular carcinoma
10.1016/j.jcmgh.2024.101454 · 2025 · External reference
Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux
10.1016/j.phrs.2020.105295 · 2021 · External reference
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy
10.1007/s10555-024-10211-9 · 2024 · External reference
Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion
10.1084/jem.20021952 · 2003 · External reference
The NRF2-CARM1 axis links glucose sensing to transcriptional and epigenetic regulation of the pentose phosphate pathway in gastric cancer
10.1038/s41419-024-07052-3 · 2024 · External reference
Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance
10.1038/s41467-023-37013-x · 2023 · External reference
Recent histone deacetylase inhibitors in cancer therapy
10.1002/cncr.34974 · 2023 · External reference
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
10.1016/j.biopha.2022.113116 · 2022 · External reference
Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α
10.1038/s41418-024-01271-z · 2024 · External reference
RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells
10.1038/s41401-019-0340-7 · 2020 · External reference
Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis
10.1046/j.1432-1033.2003.03765.x · 2003 · External reference
Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis
10.1073/pnas.1700455114 · 2017 · External reference
